دورية أكاديمية
أعرض في EDS

Bendamustine as salvage treatment for patients with relapsed or refractory mantle cell lymphoma patients: a retrospective study of the Spanish experience.

التفاصيل البيبلوغرافية
العنوان: Bendamustine as salvage treatment for patients with relapsed or refractory mantle cell lymphoma patients: a retrospective study of the Spanish experience.
المؤلفون: García-Noblejas A; Department of Hematology, Hospital Universitario La Princesa, 28006, Madrid, Spain, agnoblejas@yahoo.com., Martínez Chamorro C, Navarro Matilla B, Da Silva Rodriguez C, González-Lopez TJ, Oña Navarrete R, Ramírez Sánchez MJ, Martínez Barranco P, Sánchez Blanco JJ, Nicolás C, Pérez R, Sánchez González B, Ruedas López AM, Domingo-Domenech E, Panizo C, Macia S, Fernández-Fonseca E, Cannata-Ortiz J, Arranz R
المصدر: Annals of hematology [Ann Hematol] 2014 Sep; Vol. 93 (9), pp. 1551-8. Date of Electronic Publication: 2014 Apr 30.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9107334 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0584 (Electronic) Linking ISSN: 09395555 NLM ISO Abbreviation: Ann Hematol Subsets: MEDLINE
أسماء مطبوعة: Publication: Berlin : Springer Verlag
Original Publication: Berlin ; New York : Springer International, c1991-
مواضيع طبية MeSH: Salvage Therapy*, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Lymphoma, Mantle-Cell/*drug therapy , Nitrogen Mustard Compounds/*therapeutic use, Adult ; Aged ; Aged, 80 and over ; Bendamustine Hydrochloride ; Drug Resistance, Neoplasm/drug effects ; Female ; Humans ; Lymphoma, Mantle-Cell/epidemiology ; Lymphoma, Mantle-Cell/pathology ; Male ; Middle Aged ; Recurrence ; Retrospective Studies ; Spain/epidemiology ; Treatment Failure
مستخلص: Patients with mantle cell lymphoma (MCL) have an adverse outcome after relapse. Bendamustine has demonstrated a good efficacy and toxicity profile in previously reported trials. In this study, we present a retrospective analysis of the Spanish experience in relapsed/refractory MCL treated with bendamustine in combination or alone with the objective of knowing the efficacy and toxicity profile of this treatment in our current clinical practice. Fifty eight patients were registered: 67 % male with median age of 71 years, and 2 is the median number of previous lines. The most frequent bendamustine regimen was bendamustine plus rituximab (83 %). The median number of cycles was 5 (range 1-8). The overall response rate was 84 % with 53 % of complete response/unconfirmed complete response (CR/uCR). Median progression-free survival (PFS) was 16 months (95 % confidence interval (CI) 13.3-18.8), and for patients who achieved CR/uCR, it was 33 months (95 % CI 11.1-54.2). Median overall survival (OS) was 30 months (95 % CI 25.6-34.9). For PFS, only blastoid histology and not achieving CR after bendamustine had a significant negative impact on the univariate and multivariate analyses (p < 0.05). Nevertheless, for OS, only an elevated lactate dehydrogenase (LDH) had negative impact on both, univariate and multivariate analyses (p < 0.05). Only one case of treatment-related mortality in a 79-year-old patient with very bad performance status was reported. In 280 cycles, 12 (4 %) hospitalizations for febrile neutropenia were reported. In our population, bendamustine has been a good salvage treatment with a favorable toxicity profile in a non selected and heavily pretreated population of patients with MCL.
المشرفين على المادة: 0 (Nitrogen Mustard Compounds)
981Y8SX18M (Bendamustine Hydrochloride)
تواريخ الأحداث: Date Created: 20140501 Date Completed: 20140925 Latest Revision: 20151119
رمز التحديث: 20240628
DOI: 10.1007/s00277-014-2077-1
PMID: 24782117
قاعدة البيانات: MEDLINE
الوصف
تدمد:1432-0584
DOI:10.1007/s00277-014-2077-1